As a non-profit organization, NAF’s strategic vision is lead by our Board of Directors. They are a dynamic group of individuals that volunteer their time and resources to guide NAF towards its mission of accelerating the development of treatments and a cure while working to improve the lives of those living with Ataxia.
At our March Board Meeting, we said farewell to a few of our departing board members whose terms are over. The Board also approved the addition of four new board members to the team.
Thank You to Our Departing Board Members!
On behalf of the entire Ataxia community, thank you for your time and commitment to NAF’s mission! You were all a part of ushering NAF into an exciting era of drug development that our community so urgently needs. We know that you will continue to support NAF and stay connected to the community, but your time serving as an advisor to NAF is greatly appreciated!
Devin Cobb
Camille Daglio
Wilson Romero
Peter Schnobrich
Welcome to Our New Board Members!
We welcome you to the Ataxia community and thank you for your commitment to improving the lives of people living with Ataxia! We’re excited for the expertise that you have to offer in guiding NAF’s strategic vision. We look forward to working with you!
Mike Curtis, PhD
President of R&D at eGenesis
John Dwyer
Retired Risk Management Executive
Denise Kolpack
Retired Health Insurance Executive
Ann Riley, JD
Attorney Advisor,
US Courts
Read Our Latest Blogs
Community Response Regarding Troriluzole Delivered to FDA
NAF Team Member Joins Climbing Kili for a Cure
Unraveling Ancestry: Mary Hogan’s Journey
Tell Us Why You Think Ataxia Deserves Regulatory Flexibility
NAF Calls on the FDA to Apply Regulatory Flexibility and Accept the NDA Filing for troriluzole
Advocating for Ataxia: My Virtual Experience on Hill Day
